Since its initial approval for moderate-to-severe atopic dermatitis, Dupixent has secured approvals across eight other ...

Dupixent's new ads debut as rivals AstraZeneca and Amgen are taking an animated approach to their new DTC asthma campaign for Tezspire. (Sanofi) (Sanofi) Dupixent is a blockbuster immunology drug that ...

On Wednesday, the European Medicines Agency (EMA) approved Dupixent (dupilumab) as an add-on maintenance treatment for adults with uncontrolled chronic obstructive pulmonary disease (COPD) ...

The FDA has signed off on Sanofi and Regeneron’s megablockbuster Dupixent to treat patients with chronic spontaneous urticaria. It is the fourth new indication approval for Dupixent in the last 16 ...

Sanofi looks compelling with strong fundamentals and a robust pipeline. Click for this updated look at SNY stock and why I ...

Late-breaking presentation at ACG 2023 showed histologic and endoscopic improvements were maintained with no new safety signals to week 52 with higher dose Dupixent in these children Data reinforce ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

TARRYTOWN, N.Y. and PARIS, Sept. 13, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the U.S. Food and Drug Administration (FDA) has approved ...

Jonathan Wosen is STAT’s West Coast biotech & life sciences reporter. You can reach Jonathan on Signal at jwosen.27. Sanofi and Regeneron’s blockbuster drug Dupixent successfully treated patients with ...

Approval in CSU for children 2 to 11 years of age is based on data from the LIBERTY-CUPID clinical trial program, including an extrapolation of efficacy data showing that Dupixent significantly ...

The pharmaceutical company gains a prospective blockbuster with the deal, but is it worth $10.9 billion?